Anti-infective Drugs Market (By Product - Anti-bacterial Drugs (B-lactams, Quinolones, Macrolides, Tetracycline, Aminoglycoside, Others (Sulfonamide, Phenicols)), Anti-fungal Drugs (Azoles, Echinocandins, Polyenes), Anti-viral Drugs; Indication - Pneumonia, Methicillin-resistant Staphylococcus Aureus (MRSA), Sepsis, Tuberculosis, Dermatophytosis, Aspergillosis, Candidiasis, Hepatitis Virus Infection, HIV Infection, Respiratory Virus Infection; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, Online Sales) - Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Anti-infective Drugs market size is expected to hit around USD 194.05 billion by 2030 from valued at USD 132.56 billion in 2022 and growing at a CAGR of 4.30% from 2022 to 2030.

Growth of the market is attributed to increase in digitization of dental practices, high health care IT budgets, and rise in demand for chair time optimization in developed markets.

Anti-infective drugs are used for the purpose of killing and/or suppressing the infection causing organisms from invading the host organism by means of replication or releasing variety of toxins in the host. Such infection causing micro-organisms include viruses, bacteria, fungi, viroids, and macro parasites. Infections thus caused can be classified depending on the type of organism causing infection and the symptoms and medical signs shown by host. High prevalence and incidence rates of infectious diseases, especially viral infection, and newer drug introductions have resulted in increase in growth of global anti-infective drugs market. These factors are projected to drive demand for anti-infective drugs in the near future. Moreover, rapidly growing antibacterial resistance and unmet medical needs within antiviral therapy are expected to fuel the growth of the anti-infective drugs market.

Report Scope of the Anti-infective Drugs Market

Key Market Trends

Antiviral Products are Expected to Register High Growth Over the Forecast Period

The anti-viral agents are expected to show high growth over the forecast period, as several drug manufacturers are exploring opportunities to expand in the lower and middle-income countries, where the epidemic infection rate is high. According to the United States Centers for Disease Control and Prevention on antiviral drugs updated in August 2021, antiviral drugs are prescription medicines that are mainly used in the treatment of flu. Anti-viral drugs help reduce the risk of infection and shorten the time when the affected person is sick.  

The rise in the incidence of infectious diseases, increasing awareness among the population about such diseases and the rising number of research and development in the area is adding to the growth of the market.

Several market players have been focusing on the production and manufacturing of anti-viral drugs, owing to their increasing necessity. For instance, in October 2021, Merck & Co. Inc., a pharmaceutical company, signed a voluntary licensing agreement with Medicines Patent Pool (MPP), a United Nations-backed public health organization. The agreement focused on facilitating affordable global access to molnupiravir, an investigational oral COVID-19 antiviral medicine for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization. Such activities are expected to boost the antiviral segment growth over the forecast period.

There is high diversity in the patient pool which require long treatment procedures in hospital facilities as well as home care treatments. Moreover, there has been observed a growing interest by governments in countries showing fast economic growth, to collaborate with hospitals and global pharmaceutical companies to imporve the distribution rate of antiviral agents to the needful in the required area of a country. For instance, in November 2021, Pfizer Inc. announced an agreement with the United States government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID. The company had also entered into several advance purchase agreements with various other countries and had initiated bilateral outreach to approximately 100 countries around the world. Such factors are expected to boost the growth of antivirals segment over the forecast period.

Anti-infective Drugs Market: Segmentation

The global anti-infective drugs market has been segmented based on type, indication, distribution channel, and region. In terms of type, the global market has been categorized into anti-bacterial drugs, anti-fungal drugs, and anti-viral drugs. The anti-viral drugs segment accounted for significant share of the global market in terms of revenue in 2016. The segment is expected to expand at a rapid pace during the forecast period. It is likely to gain market share by the end of 2025. This is attributed to increase in prevalence of viral infection, especially HIV infection, hepatitis virus infection, and others.

In terms of indication, the global anti-infective drugs market has been classified into pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), sepsis, tuberculosis, dermatophytosis, aspergillosis, candidiasis, hepatitis virus infection, HIV infection, respiratory virus infection, and others. The HIV infection segment dominated the global market and the trend is likely to continue by the end of 2025 with marginal increase in market share. The HIV infection segment is projected to dominate the global anti-infective drugs market as these drugs are administered to patients for the lifetime and new and effective treatments are being introduced. Based on distribution channel, the global market has been divided into hospital pharmacy, retail pharmacy and online pharmacy. 

Geographically, the global anti-infective drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market and is projected to lose market share by the end of 2025. The region’s dominance of the global anti-infective drugs market is due to factors such as increase in adoption of advanced and high cost drug therapies and significant treatment penetration. Moreover, patients with HIV infection and hepatitis virus infection have increased in the U.S. This is projected to fuel the growth of the anti-infective drugs market in the country during the forecast period. Asia Pacific is projected to be the fastest growing market for anti-infective drugs during the forecast period. India dominated the anti-infective drugs market in the region, whereas Japan is estimated to grow at a high CAGR during the forecast period.

North America is estimated to Have Largest Share over the Forecast Period

The North American region is expected to contribute significantly to the market growth during the study period. Factors such as a sophisticated healthcare infrastructure, high awareness in society, well-established distribution channels, and a good presence of e-commerce across the United States and Canada is expected to drive the market over the forecast period.

The United States Center for Disease Control and Prevention (CDC) advocates the use of antivirals for various infectious diseases. For instance, in September 2021, the CDC published a brochure supporting the use of antiviral drugs for the treatment of influenza. The CDC suggested the use of four drugs approved by the Food and Drug Administration, oseltamivir phosphate, zanamivir, peramivir, and baloxavir marboxil. Such activities by governmental health organizations promoting the use of antivirals in the nation are expected to propel the growth of the market over the forecast period.

The high purchasing power of the end consumer and favorable reimbursement policies help pharmaceutical companies to grow in this region. Further, it helps the pharmaceutical companies increase their production capabilities, and invest more in funded projects with renowned medical institutions to suffice the demand for anti-infective drugs across North America.

Several key market players are also aiding the growth of the market. For instance, in May 2022, the United States Food and Drug Administration approved VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK manufactured by Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. Such instances are projected to boost the growth of the market over the forecast period.

Some of the prominent players in the Anti-infective Drugs Market include:

Merck & Co., Inc., Bayer AG, Pfizer, Inc., Gilead Sciences, GlaxoSmithKline plc, Novartis AG, Bristol-Myers Squibb, Sanofi, Allergen plc, F. Hoffman-La Roche Ltd.,

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Anti-infective Drugs market

By Product Type

• Anti-bacterial Drugs
• B-lactams
• Quinolones
• Macrolides
• Tetracycline
• Aminoglycoside
• Others (sulfonamide, phenicols)
• Anti-fungal Drugs
• Azoles
• Echinocandins
• Polyenes
• Others
• Anti-viral Drugs

By Indication

·       HIV Infection

·       Pneumonia

·       Respiratory Virus Infection

·       Sepsis

·       Tuberculosis

By Distribution Channel

·       Hospital Pharmacy

·       Retail Pharmacy

·       Other Distribution Channels

Other Indications

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Anti-infective Drugs industry analysis from 2022 to 2030 to identify the prevailing Anti-infective Drugs industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Anti-infective Drugs industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Anti-infective Drugs industry trends, key players, market segments, application areas, and market growth strategies.